Is tissue CA125 expression in epithelial ovarian adenocarcinoma heterogenic?

APMIS

Volumn 121, Issue 1, 2013, Pages 38-44

  Sparholt, Morten H ^a   Høgdall, Claus K ^a   Nedergaard, Lotte ^a   Heeran, Mel C J ^a   Christensen, Ib J ^b   Høgdall, Estrid V S ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

CA125; Heterogeneity; Immunohistochemistry; Individual treatment; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; OREGOVOMAB;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GRADING; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; METASTASIS; OVARY ADENOCARCINOMA; PREOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; STATISTICS, NONPARAMETRIC; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871670456     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2012.02943.x     Document Type: Article

References (9)

1. Høgdall CK, Nielsen MLS, Taaning L. Year Report 2009/2010. Danish Gynecologic Cancer Database. A Nationwide Clinical Database for Cancer in Ovaries, Uterus and Cervix. Copenhagen: Lægeforeningens forlag, 2012: 1-85. ISNN: 1902-7877 (paper), ISNN: 1903-0223 (online).
2. Sparholt MH, Høgdall EVS, Høgdall CK. Tumormarkører ved epithelial ovariecancer. Ugeskr Laeger 2009;171/48:3505-9.
3. Høgdall EVS, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther S, et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From the Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol 2007;104:508-15.
4. Frederick PJ, Straughn JM Jr, Alvarez RD, Buchsbaum DJ. Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. Gynecol Oncol. 2009;113:384-90.
5. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002;2:331-41.
6. Marjioni VM. Immunohistochemistry in gynaecological pathology: a review. Pathology 2004;36:109-19.
7. Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 2009;27:418-25.
8. Høgdall E. Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 2008; 20:4-8. Review.
9. Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J Jr, et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 2004;22:3507-16.